Re­ci­phar­m's glob­al deal spree con­tin­ues with ac­qui­si­tion of Por­tuguese CD­MO

Fol­low­ing a mon­ster 2021, in which CD­MO Re­ci­pharm ex­pand­ed its foot­print across the world in places with a small­er man­u­fac­tur­ing pres­ence, it’s ex­pand­ing its foot­print in a Eu­ro­pean coun­try where it’s al­ready es­tab­lished: Por­tu­gal.

The Swedish com­pa­ny an­nounced its ac­qui­si­tion of GenI­bet, a CD­MO based in Oeiras, Por­tu­gal that was spun out of an iBET – In­sti­tu­to de Bi­olo­gia Ex­per­i­men­tal e Tec­nológ­i­ca – lab in 2016.  The move will help Re­ci­pharm build out its bi­o­log­ics ca­pa­bil­i­ties, and ben­e­fit from GenI­bet’s ex­pe­ri­ence with vi­ral vec­tors and vac­cines, as it looks to fo­cus on the man­u­fac­tur­ing of nov­el ad­vanced ther­a­py med­i­cines. It will in­her­it GenI­bet’s 70 em­ploy­ees at the near­by site just 11 km from Re­ci­pharm’s fa­cil­i­ty in Lis­bon.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER